Drug-loaded nanocarriers : passive targeting and crossing of biological barriers
dc.contributor.author | Rabanel, Jean-Michel | |
dc.contributor.author | Aoun, Valery | |
dc.contributor.author | Elkin, Igor | |
dc.contributor.author | Mokhtar, Mohamed | |
dc.contributor.author | Hildgen, Patrice | |
dc.date.accessioned | 2015-11-18T17:42:34Z | |
dc.date.available | NO_RESTRICTION | fr |
dc.date.available | 2015-11-18T17:42:34Z | |
dc.date.issued | 2012-12 | |
dc.identifier.uri | http://hdl.handle.net/1866/12636 | |
dc.subject | Nanocarrier | fr |
dc.subject | Drug delivery | fr |
dc.subject | Biological barriers | fr |
dc.subject | Passive targeting | fr |
dc.subject | Surface properties | fr |
dc.subject | Vascular endothelium | fr |
dc.subject | Oral administration | fr |
dc.subject | Pulmonary administration | fr |
dc.title | Drug-loaded nanocarriers : passive targeting and crossing of biological barriers | fr |
dc.type | Article | fr |
dc.contributor.affiliation | Université de Montréal. Faculté de pharmacie | fr |
UdeM.statut | Étudiant(e) aux cycles supérieurs / Graduate Student | fr |
dc.identifier.doi | 10.2174/092986712800784702 | |
dcterms.abstract | Poor bioavailability and poor pharmacokinetic characteristics are some of the leading causes of drug development failure. Therefore, poorly-soluble drugs, fragile proteins or nucleic acid products may benefit from their encapsulation in nanosized vehicles, providing enhanced solubilisation, protection against degradation, and increased access to pathological compartments. A key element for the success of drug-loaded nanocarriers (NC) is their ability to either cross biological barriers themselves or allow loaded drugs to traverse them to achieve optimal pharmacological action at pathological sites. Depending on the mode of administration, NC may have to cross different physiological barriers in their journey towards their target. In this review, the crossing of biological barriers by passive targeting strategies will be presented for intravenous delivery (vascular endothelial lining, particularly for tumour vasculature and blood-brain barrier targeting), oral administration (gastrointestinal lining) and upper airway administration (pulmonary epithelium). For each specific barrier, background information will be provided on the structure and biology of the tissues involved as well as available pathways for nano-objects or loaded drugs (diffusion and convection through fenestration, transcytosis, tight junction crossing, etc.). The determinants of passive targeting − size, shape, surface chemistry, surface patterning of nanovectors − will be discussed in light of current results. Perspectives on each mode of administration will be presented. The focus will be on polymeric nanoparticles and dendrimers although advances in liposome technology will be also reported as they represent the largest body in the drug delivery literature. | fr |
dcterms.isPartOf | urn:ISSN:1875-533X | |
dcterms.isPartOf | urn:ISSN:0929-8673 | |
dcterms.language | eng | fr |
UdeM.VersionRioxx | Version acceptée / Accepted Manuscript | |
oaire.citationTitle | Current medicinal chemistry | |
oaire.citationVolume | 19 | |
oaire.citationIssue | 19 | |
oaire.citationStartPage | 3070 | |
oaire.citationEndPage | 3102 |
Fichier·s constituant ce document
Ce document figure dans la ou les collections suivantes
Ce document diffusé sur Papyrus est la propriété exclusive des titulaires des droits d'auteur et est protégé par la Loi sur le droit d'auteur (L.R.C. (1985), ch. C-42). Il peut être utilisé dans le cadre d'une utilisation équitable et non commerciale, à des fins d'étude privée ou de recherche, de critique ou de compte-rendu comme le prévoit la Loi. Pour toute autre utilisation, une autorisation écrite des titulaires des droits d'auteur sera nécessaire.